Onyx Pharmaceuticals Reports Third Quarter 2009 Financial Results; Nexavar Global Net Sales Top $229 Million, 27% Increase Over Third Qu...( Shares used in comp...),Health

Date:11/3/2009

===== ===== ===== ===== Shares used in computing net income per share: Basic 60,248 56,197 58,201 55,755 ====== ====== ====== ====== Diluted (2) 60,624 57,194 58,511 56,773 ====== ====== ====== ====== (1) Includes employee stock-based compensation charges of: Research and development $517 $694 $2,286 $2,083 Selling, general, and administrative 4,455 3,646 12,647 11,726 ----- ----- ------ ------ Total employee stock- based compensation $4,972 $4,340 $14,933 $13,809 ====== ====== ======= ======= (2) Computation of diluted net income per share: Net income $8,233 $12,243 $21,672 $32,135 Add: Interest and issuance costs related to dilutive convertible senior notes (3) - - - - ----- ----- ----- ----- Net income - diluted $8,233 $12,243 $21,672 $32,135 ====== ======= ======= ======= Basic shares 60,248 56,197 58,201 55,755 Dilutive effect of options and restricted stock 376 997 310 1,018 Dilutive effect of convertible senior notes (3) - - - - ----- ----- ----- ----- Diluted shares 60,624 57,194 58,511 56,773 ====== ====== ====== ====== (3) Under the "if-converted" method, potential common shares relate
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Cumberland Pharmaceuticals to Present at Lazard Healthcare Conference in New York on November 17, 2009
2. Vanda Pharmaceuticals Reports Third Quarter 2009 Results
3. Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
4. VIA Pharmaceuticals Featured at Cambridge Healthtech Institute Discovery on Target 2009 Conference
5. Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
6. Amira Pharmaceuticals to Present at the BIO Investor Forum in San Francisco
7. Positive Data from Arena Pharmaceuticals Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
8. DUSA Pharmaceuticals Named to Deloittes 2009 Technology Fast 500 List of Fastest Growing Companies in North America
9. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
10. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
11. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference